Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanosomal Docetaxel Lipid Suspension vs Taxotere in Triple-Negative Breast Cancer
NCT03671044Phase 3Recruiting
- Sponsor
- Jina Pharmaceuticals, Inc.
- Start
- Jul 2018
- Primary completion
- May 2025
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 2
01
Overview
A Phase 3 trial of nanosomal docetaxel lipid suspension in triple-negative breast cancer (TNBC), sponsored by Jina Pharmaceuticals, Inc.. Started Jul 2018; status: recruiting.
02
Drugs
nanosomal docetaxel lipid suspension
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03671044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03671044.